Randomized Controlled Study to Examine the Effectiveness of Fibroblast Interferon as an Adjuvant Therapy in Gastric Carcinoma Operated for Cure

1982 ◽  
pp. 224-226
Author(s):  
Ch. Herfarth ◽  
P. Schlag ◽  
W. Schreml
Keyword(s):  
Adjuvant Therapy ◽  
Gastric Carcinoma ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Randomized Controlled

scholarly journals CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study

2021 ◽  
Author(s):  
Ya A. Shliakhtunou
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Adjuvant Therapy ◽  
Prospective Study ◽  
Metastatic Breast ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Control Group ◽  
Randomized Controlled ◽  
Experimental Group

Abstract The aim To conduct a prospective randomized controlled study of the optimization of adjuvant therapy in patients with non-metastatic breast cancer, taking into account the presence of circulating tumor cells (CTCs) with an assessment of tumor-specific OS and DFS. Materials Stage 1 Continuous non-randomized prospective study (n = 102) to study the clinical and prognostic value of CTCs and evaluate the effectiveness of adjuvant systemic therapy in relation to CTC eradication; Stage 2 Prospective randomized controlled study (n = 128) of optimization of adjuvant therapy taking into account CTCs with an assessment of the effectiveness of the standard therapy and an optimized therapy regimen. Results Monitoring of CTCs during adjuvant drug treatment has established that a significant decrease in the frequency of CTC identification can be achieved only by sequential administration of anthracyclines and taxanes (paclitaxel) AC-T, which allows reducing CTCs compared to other regimens from 52.6 to 15.8% (p = 0.006). CTC-oriented personalized adjuvant therapy in the experimental group, based on the timely transition from an ineffective adjuvant chemotherapy regimen to taxanes, as well as additional monochemotherapy with gemcitabine can achieve 100% eradication CTCs. In the adjuvant therapy experimental group taking into account CTCs (n = 68), the OS 5-year tumor-specific rate was 90.3 ± 3.8%, (control group 78.7 ± 3.9%, p = 0.036). DFS tumor-specific in the experimental group was 88.0 ± 4.4%, (control group 80.6 ± 3.3%, p = 0.023). Conclusions The use of the method of treatment of CTC-oriented personalized adjuvant therapy for non-metastatic breast cancer makes it possible to reliably increase DFS 5-year by 7.4% and OS 5-year by 11.6%.

scholarly journals Management of Women with Surgically Staged 1 Uterine Papillary Serous Cancer

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Laurie Elit ◽  
Andre LaRoche ◽  
Lauren Smith ◽  
John Mazurka ◽  
Francois Moens ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Literature Search ◽  
Residual Disease ◽  
Case Series ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Time Of Surgery ◽  
Randomized Controlled ◽  
Stage 1

Objective. To review the management and outcomes of women with surgically staged 1 UPSC. Methods. We report on a case series from 2008–2010 from Hamilton Canada. We summarize the data from a literature search on surgically staged 1 UPSC. Results. There is a group women with Stage 1A UPSC with no residual disease at time of surgery who do not require adjuvant therapy. Vault recurrences appear to be lower in women who received adjuvant vault radiation. Chemotherapy appears to confer longer survival for those women with Stage 1B or 1C disease compared of those observed or who had radiation alone. Conclusion. Adjuvant therapy appears to confer benefit in certain groups of women with stage 1 UPSC. A randomized controlled study would clarify the degree of benefit.

Sign in / Sign up

Export Citation Format

Share Document